KRAS and colorectal carcinoma: Analysis of these downregulated genes related to the MAPK and PI3K/Akt signaling pathways will shed light on how ERK1/2 and Akt1/2/3 were perturbed in CRC primary tumors independent of KRAS oncogenic mutants.